At the helm of this initiative are three esteemed principal investigators: Dr. Cassandra Vieten, a clinical professor in the Department of Family Medicine at UC San Diego; Dr. Gene “Rusty” Kallenberg, professor emeritus and founding director of the Centers for Integrative Health; and Dr. Ryan Bradley, an associate professor at UC San Diego’s Herbert Wertheim School of Public Health and Human Longevity Science. Their combined expertise spans clinical, integrative, and public health disciplines, positioning the REACH Center to lead pioneering research that bridges scientific discovery and real-world application. The initiative embraces the principle that effective healthcare transcends the isolated treatment of organs or systems and instead focuses on the complex interplay of biological, psychological, and social determinants.

Whole person health stresses the importance of coordinated multidisciplinary care tailored to respect patients’ values and beliefs. This approach recognizes that conventional medicine’s specialization has propelled advancements in treating specific diseases but has largely overlooked holistic, systemic perspectives essential for sustained health outcomes. Dr. Vieten highlights this gap by emphasizing that humans are integrated entities rather than discrete organ systems, necessitating innovative research frameworks that integrate complementary modalities. This visionary perspective directs the REACH Center’s mission to integrate traditional and integrative health disciplines, addressing an urgent need in contemporary clinical research.

The REACH Center’s mission involves fostering robust partnerships with accredited institutions specializing in Complementary and Integrative Health (CIH) modalities—including acupuncture, East Asian Medicine, naturopathy, and physical therapy-generated interventions. Despite their widespread educational offerings, these institutions have historically lacked access to advanced research infrastructure, funding opportunities, and cutting-edge technologies essential for translational science endeavors. By providing a virtual resource hub, UC San Diego offers these institutions unprecedented access to one of the world’s leading biomedical research ecosystems. This collaboration stands to elevate CIH academic and clinical faculties to new heights of research excellence.

Central to these efforts, the REACH Center will initially support a cohort of at least 26 research scholars drawn from six distinct CIH institutions. These emerging scientists will enter a rigorous two-year career advancement program designed to cultivate expertise in translational research methodologies. Each scholar will be paired with mentors from UC San Diego and allied University of California campuses, such as UC Irvine’s Samueli Institute for Integrative Medicine, UC Davis’s Center for Integrative Medicine, UCSF’s Osher Center for Integrative Health, and UCLA’s David Geffen School of Medicine. This mentorship network provides both scholarly guidance and access to interdisciplinary collaborative platforms, significantly enhancing research quality and impact.

Participants will receive specialized micro-credential training focused on cutting-edge research techniques designed to translate fundamental discoveries into tangible health interventions. This includes critical guidance on developing pilot studies that adhere to stringent scientific standards, preparing them for competitive grant submissions. The scholars will also gain privileged access to UC San Diego’s state-of-the-art core facilities, such as the CIT Biomarker Laboratory, researchers at the Center for Microbiome Innovation housed within the Jacobs School of Engineering, and the Altman Clinical and Translational Research Institute. These resources provide the technological backbone necessary to propel whole person health research to the forefront of biomedical innovation.

Alongside career training, the REACH Center will allocate funding for 15 to 30 pilot grants annually to support burgeoning research initiatives within CIH institutions. These grants are explicitly structured to overcome barriers often encountered in integrative health research, such as limited sample sizes, insufficient statistical power, and restricted access to comprehensive clinical datasets. Leveraging University of California’s broad patient populations and technology platforms, these funded projects will aim to develop rigorous, scalable, and generalizable evidence addressing clinical efficacy and mechanisms of action across integrative modalities.

Dr. Ryan Bradley underscores the strategic importance of this NIH initiative in fostering sustained research capacity by systematically building infrastructure and faculty competencies at CIH academic centers. Simultaneously, UC San Diego anticipates reciprocal scientific benefits through enhanced collaborative research that interrogates specific biological mechanisms, compares modality effectiveness, and elucidates patient-specific responses. Such insights are critical for delineating personalized therapeutic pathways and optimizing integrative medicine’s role within broader healthcare paradigms.

Over the five-year grant tenure, the REACH Center intends to catalyze a significant expansion in the quantity and caliber of research grant submissions originating from complementary and integrative health universities. Establishing long-term collaborative frameworks will ensure retention of skilled investigators within this niche field, nurturing a thriving research ecosystem. The anticipated outcomes include the generation of high-impact, evidence-based models that inform clinical practice, guide healthcare policy, and drive innovation toward more inclusive, patient-centered care.

The process of elevating research quality will likely commence through joint grant submissions co-led by UC San Diego and CIH institutions, leveraging shared expertise and infrastructure. The inaugural cohort of REACH trainees is slated to begin their training in January 2026, with immediate opportunities available for pilot grant applications. This timeline reflects a deliberate commitment to rapidly embed translational science capacities within CIH academia, propelling these disciplines into mainstream biomedical research.

Dr. Kallenberg further emphasizes that this initiative not only bolsters external CIH institutions but also enriches UC San Diego’s own Complementary and Integrative Health faculty. The establishment of a collaborative educational and research environment fosters intellectual exchange, cross-disciplinary projects, and shared training activities. This integrative strategy positions the REACH Center as a catalyst for systemic change in how healthcare research is conceptualized, funded, and translated into clinical practice.

In summary, this unprecedented NIH-funded REACH initiative marks a critical milestone in the evolution of whole person health research. By bridging the gap between complementary and integrative health education and translational biomedical science, the program enables the development of scientifically rigorous evidence supporting holistic health interventions. The resulting innovations promise to transform clinical outcomes and health policy, underscoring the profound importance of integrating physical, emotional, social, and cultural dimensions of health within modern medicine.

—

Subject of Research: Whole Person Health and Translational Science in Complementary and Integrative Health

Article Title: UC San Diego Launches REACH Center to Revolutionize Whole Person Health Research

News Publication Date: Information not provided

Web References:
– https://cih.ucsd.edu/
– https://www.nccih.nih.gov/health/whole-person-health-what-it-is-and-why-its-important
– https://cih.ucsd.edu/mindfulness
– https://rheumatology.ucsd.edu/research/center-for-innovative-therapy/biomarker-laboratory/index.html
– https://cmi.ucsd.edu/
– https://actri.ucsd.edu/

Keywords: Clinical Research, Translational Medicine, Whole Person Health, Integrative Health, Complementary Medicine, Biomedical Research, Translational Science, Integrative Medicine, NIH Grant, Career Development, Pilot Studies

Dr. Schork’s leadership inaugurates a new era within HonorHealth’s recently established Center for Translational Science, where his team will pioneer research that bridges molecular insights with clinical applications. Precision medicine, which tailors prevention and therapeutic strategies to the individual’s unique molecular and genetic profile, forms the backbone of this initiative. The focus is on “interception” — detecting and mitigating disease processes before they manifest clinically — thereby revolutionizing traditional paradigms of reactive healthcare.

The concept of medical interception challenges the binary understanding of disease presence. Instead of viewing disease simply as either absent or symptomatic, it frames disease as a progressive biological continuum. Early pathobiological processes unfold subtly over time, producing measurable molecular signals long before overt symptoms arise. Dr. Schork’s work centers on elucidating these underlying processes and developing strategies to intervene at these nascent stages, potentially halting disease progression altogether.

Leveraging multi-modal biomarker technologies, future clinical assessments may employ genome sequencing, proteomics of bodily fluids such as blood or cerebrospinal fluid, and advanced metabolomic approaches to identify patients at risk for complex diseases like cancer or cardiovascular disorders well ahead of symptom onset. The integration of wearable biosensors and advanced imaging modalities will enable continuous health monitoring, creating dynamic health profiles and allowing clinicians to tailor timely preventative interventions based on individual risk trajectories.

A particularly transformative aspect of Dr. Schork’s approach involves the deployment of Artificial Intelligence (AI) and machine learning algorithms to mine vast electronic health record databases containing billions of data points. These sophisticated computational techniques can uncover intricate, non-obvious patterns that escape human detection, enabling the prediction of disease risk and the design of personalized treatment regimens with unprecedented precision. Such AI-driven insights promise to enhance diagnostic accuracy, reduce clinical errors, and customize care pathways in ways that were previously unattainable.

Early experimental applications of AI models in clinical contexts have demonstrated notable improvements in diagnostic sensitivity and specificity, especially when integrated with genomic and phenotypic data. However, Dr. Schork emphasizes the critical necessity of rigorous clinical validation to translate these insights safely and effectively into patient care. He advocates for an iterative loop of translational research where discoveries feed directly into clinical trials and patient interventions, thereby accelerating the adoption of cutting-edge science at the bedside.

Leadership at HonorHealth has expressed enthusiastic support for these innovative directions. Dr. Michael Gordon, Medical Director of the Research Institute, highlights the institute’s commitment to extending healthy lifespan by emphasizing prevention and early intervention across disease spectra. Whether intercepting cancer, cardiovascular disease, or other chronic conditions, the goal is to identify highly sensitive diagnostic markers that enable intervention before functional decline or symptomatic disease emerges, preserving patients’ quality of life.

Mark Slater, Ph.D., CEO of the HonorHealth Research Institute and Vice President of Research at HonorHealth, underscores Dr. Schork’s exceptional capacity to integrate data science with clinical and basic biomedical research. His extensive network of national and international collaborators is expected to strengthen the institute’s alliances, notably advancing partnerships with academic entities like Arizona State University’s emerging School of Medicine and Advanced Medical Engineering. This collaborative synergy will catalyze translational breakthroughs spanning molecular biology, computational analytics, and clinical medicine.

Sunil Sharma, M.D., MBA, Director of the Center for Translational Science, praises Dr. Schork’s multidisciplinary expertise, describing him as a visionary “renaissance man” with a rare blend of computational genius and imaginative scientific rigor. His computational methods and analytic frameworks are anticipated to be transformative forces, fostering innovation and driving the development of new interventions that intercept disease processes with unprecedented efficacy.

Dr. Schork’s distinguished career encompasses leadership roles at premier research institutions including the Translational Genomics Research Institute (TGen), where he directed the Division of Clinical Genomics and Therapeutics. His academic appointments span City of Hope, the University of California San Diego, Scripps Research Institute, the J. Craig Venter Institute, and others, reflecting a broad and deep engagement with genomics, biostatistics, clinical trials, and translational medicine. His prolific scholarly output exceeds 600 peer-reviewed publications, contributing novel methodologies and integrated disease models critical to advancing biomedical science.

His research portfolio reflects extensive contributions to the design and analysis of clinical trials, development of integrated analytic methodologies, and consortium-based collaborative studies. These endeavors leverage large-scale data integration from diverse biological and clinical sources to elucidate the mechanisms driving disease onset, progression, and response to therapy. Such integrative approaches are foundational for enabling personalized interception strategies that optimize health trajectories for at-risk individuals.

HonorHealth Research Institute, headquartered in Scottsdale, Arizona, is an internationally recognized clinical research destination dedicated to enhancing patient outcomes through innovative trials and therapeutic options. With a multidisciplinary team of experts and robust national collaborations, the institute offers patients access to next-generation health innovations, ensuring early adoption of promising treatments that redefine standards of care.

Patients interested in participating in HonorHealth’s clinical studies or seeking more information about cutting-edge research initiatives can contact the institute directly to engage with a team committed to transforming medicine through science and technology.

Subject of Research: People
News Publication Date: August 14, 2025
Web References: HonorHealth.com/research
Keywords: Diseases and disorders, Health care, Human health